Generic placeholder image

Current Molecular Pharmacology

Editor-in-Chief

ISSN (Print): 1874-4672
ISSN (Online): 1874-4702

Research Article

CircRNA 001418 Promoted Cell Growth and Metastasis of Bladder Carcinoma via EphA2 by miR-1297

Author(s): Guorui Peng, Hongxue Meng, Hongxin Pan and Wentao Wang*

Volume 14, Issue 1, 2021

Published on: 05 May, 2020

Page: [68 - 78] Pages: 11

DOI: 10.2174/1874467213666200505093815

Price: $65

Abstract

Background: Cancer is one of the major causes of human deaths at present. It is the leading cause of deaths in developed countries. Moreover, Circular RNAs (circRNAs) have been discovered to play important roles in tumor genesis and development and are abnormally expressed in bladder cancer .

Objective: The present study aims to investigate the anti-cancer effects of circ 001418 on bladder carcinoma and its possible mechanism.

Methods: Quantitative PCR (qPCR) and gene chip were used to measure the circ 001418 expression. Cell proliferation and transfer, apoptosis and caspase-8 and caspase-3 activity levels were measured using MTT, Transwell assay, Flow cytometry. Caspase-3 and 9 activity levels, EphA2, cytochrome c and FADD protein expression, were detected using Western blotting.

Results: The expression of circ 001418 was increased in patients with bladder carcinoma. Over-expression of circ 001418 promoted cell proliferation and transfer, and reduced apoptosis in vitro model of bladder carcinoma. Down-regulation of Circ 001418 inhibited cell proliferation and transfer, and induced apoptosis in vitro model of bladder carcinoma. Meanwhile, over-expression of circ 001418 induced EphA2 and cytochrome c protein expression, and suppressed FADD protein expression in vitro model of bladder carcinoma by the suppression of miR-1297. MiR-1297 reduced the pro-cancer effect of circ 001418 on apoptosis of bladder carcinoma.

Conclusion: Results showed that circRNA 001418 promoted cell growth and metastasis of bladder carcinoma via EphA2 by miR-1297.

Keywords: Circ 001418, bladder carcinoma, miR-1297, FADD, cytochrome c, EPHA2.

Graphical Abstract
[1]
Tandogdu, Z.; Lewis, R.; Duncan, A.; Penegar, S.; McDonald, A.; Vale, L.; Shen, J.; Kelly, J.D.; Pickard, R.; N Dow, J.; Ramsay, C.; Mostafid, H.; Mariappan, P.; Nabi, G.; Creswell, J.; Lazarowicz, H.; McGrath, J.; Taylor, E.; Clark, E.; Maclennan, G.; Norrie, J.; Hall, E.; Heer, R. PHOTO Trial Management Group. Photodynamic versus white light-guided treatment of non-muscle invasive bladder cancer: a study protocol for a randomised trial of clinical and cost-effectiveness. BMJ Open, 2019, 9(9)e022268
[http://dx.doi.org/10.1136/bmjopen-2018-022268] [PMID: 31481549]
[2]
Pardini, B.; Cordero, F.; Naccarati, A.; Viberti, C.; Birolo, G.; Oderda, M.; Di Gaetano, C.; Arigoni, M.; Martina, F.; Calogero, R.A.; Sacerdote, C.; Gontero, P.; Vineis, P.; Matullo, G. microRNA profiles in urine by next-generation sequencing can stratify bladder cancer subtypes. Oncotarget, 2018, 9(29), 20658-20669.
[http://dx.doi.org/10.18632/oncotarget.25057] [PMID: 29755679]
[3]
Arnold, E.J.; Childress, M.O.; Fourez, L.M.; Tan, K.M.; Stewart, J.C.; Bonney, P.L.; Knapp, D.W. Clinical trial of vinblastine in dogs with transitional cell carcinoma of the urinary bladder. J. Vet. Intern. Med., 2011, 25(6), 1385-1390.
[http://dx.doi.org/10.1111/j.1939-1676.2011.00796.x] [PMID: 22092632]
[4]
Galsky, M.D.; Hahn, N.M.; Wong, B.; Lee, K.M.; Argiriadi, P.; Albany, C.; Gimpel-Tetra, K.; Lowe, N.; Shahin, M.; Patel, V.; Tsao, C.K.; Oh, W.K. Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma. Cancer Chemother. Pharmacol., 2015, 76(6), 1259-1265.
[http://dx.doi.org/10.1007/s00280-015-2884-7] [PMID: 26464352]
[5]
Cambier, S.; Sylvester, R.J.; Collette, L.; Gontero, P.; Brausi, M.A.; van Andel, G.; Kirkels, W.J.; Silva, F.C.; Oosterlinck, W.; Prescott, S.; Kirkali, Z.; Powell, P.H.; de Reijke, T.M.; Turkeri, L.; Collette, S.; Oddens, J. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. Eur. Urol., 2016, 69(1), 60-69.
[http://dx.doi.org/10.1016/j.eururo.2015.06.045] [PMID: 26210894]
[6]
Yao, Y; Hua, Q; Zhou, Y; Shen, H. CircRNA has_circ_0001946 promotes cell growth in lung adenocarcinoma by regulating miR-135a-5p/SIRT1 axis and activating Wnt/beta-catenin signaling pathway. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie , 2019, 111, 1367-1375.
[7]
Hu, X.; Chen, L.; Wu, S.; Xu, K.; Jiang, W.; Qin, M.; Zhang, Y.; Liu, X. Integrative Analysis Reveals Key Circular RNA in Atrial Fibrillation. Front. Genet., 2019, 10, 108.
[http://dx.doi.org/10.3389/fgene.2019.00108] [PMID: 30838031]
[8]
Hu, Y.; Cheng, C.; Hong, Z.; Shi, Z. Independent prognostic miRNAs for bladder urothelial carcinoma. Oncol. Lett., 2017, 14(3), 3001-3005.
[http://dx.doi.org/10.3892/ol.2017.6471] [PMID: 28928837]
[9]
Jin, N.; Jin, X.; Gu, X.; Na, W.; Zhang, M.; Zhao, R. Screening biomarkers of bladder cancer using combined miRNA and mRNA microarray analysis. Mol. Med. Rep., 2015, 12(2), 3170-3176.
[http://dx.doi.org/10.3892/mmr.2015.3739] [PMID: 25955758]
[10]
Kent, MS; Zwingenberger, A; Westropp, JL; Barrett, LE; Durbin-Johnson, BP; Ghosh, P; Vinall, RL MicroRNA profiling of dogs with transitional cell carcinoma of the bladder using blood and urine samples , 2017, 13(1), 339.
[http://dx.doi.org/10.1186/s12917-017-1259-1]
[11]
Abraham, S.; Knapp, DW.; Cheng, L.; Snyder, PW.; Mittal, SK.; Bangari, DS.; Kinch, M.; Wu, L.; Dhariwal, J.; Mohammed, SI. Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clinical cancer research : An official journal of the American Association for Cancer Research , 2006, 12(2), 353-360.
[12]
Huddart, R.A.; Hall, E.; Hussain, S.A.; Jenkins, P.; Rawlings, C.; Tremlett, J.; Crundwell, M.; Adab, F.A.; Sheehan, D.; Syndikus, I.; Hendron, C.; Lewis, R.; Waters, R.; James, N.D. Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004). Int. J. Radiat. Oncol. Biol. Phys., 2013, 87(2), 261-269.
[http://dx.doi.org/10.1016/j.ijrobp.2013.06.2044] [PMID: 23958147]
[13]
Mata, D.A.; Groshen, S.; Von Rundstedt, F.C.; Skinner, D.G.; Stadler, W.M.; Cote, R.J.; Stein, J.P.; Lerner, S.P. Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. J. Surg. Oncol., 2015, 111(7), 923-928.
[http://dx.doi.org/10.1002/jso.23903] [PMID: 25873574]
[14]
Gao, W; Cao, Y; Guo, P; Bao, X; Zhu, H; Zheng, J; Yao, C; Chen, D; Yu, S; Chen, B; Zhou, S; Pang, D; Chen, W. Downregulation of MiR-1297 predicts poor prognosis and enhances gastric cancer cell growth by targeting CREB1. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, 105, 413-419.
[15]
Zhu, K.; Niu, L.; Wang, J.; Wang, Y.; Zhou, J.; Wang, F.; Cheng, Y.; Zhang, Q.; Li, H. Circular RNA hsa_circ_0000885 Levels are Increased in Tissue and Serum Samples from Patients with Osteosarcoma. Med. Sci. Monit., 2019, 25, 1499-1505.
[http://dx.doi.org/10.12659/MSM.914899] [PMID: 30802235]
[16]
Wu, Q.; Li, P.; Wu, M.; Liu, Q. Deregulation of Circular RNAs in Cancer From the Perspectives of Aberrant Biogenesis, Transport and Removal. Front. Genet., 2019, 10, 16.
[http://dx.doi.org/10.3389/fgene.2019.00016] [PMID: 30774645]
[17]
Li, W.T.; Zheng, H.; Nguyen, V.; Wang-Rodriguez, J.; Ongkeko, W.M. Functional Genomics Profiling of Bladder Urothelial Carcinoma MicroRNAome as a Potential Biomarker. Neoplasia, 2018, 20(4), 364-373.
[http://dx.doi.org/10.1016/j.neo.2018.01.008] [PMID: 29544183]
[18]
Garcia-Monclus, S.; Lopez-Alemany, R.; Almacellas-Rabaiget, O.; Herrero-Martín, D.; Huertas-Martinez, J.; Lagares-Tena, L.; Alba-Pavón, P.; Hontecillas-Prieto, L.; Mora, J.; de Álava, E.; Rello-Varona, S.; Giangrande, PH.; Tirado, OM. MicroRNA-26b Enhances the Radiosensitivity of Hepatocellular Carcinoma Cells by Targeting EphA2. The Tohoku journal of experimental medicine , 2018, 238(2), 143-151.
[19]
Jin, Q.; Li, X.J.; Cao, P.G. MicroRNA-26b Enhances the Radiosensitivity of Hepatocellular Carcinoma Cells by Targeting EphA2. Tohoku J. Exp. Med., 2016, 238(2), 143-151.
[http://dx.doi.org/10.1620/tjem.238.143] [PMID: 26843134]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy